Aesthetic, body composition, and dermal architecture - addressed clinically, not cosmetically.
Vivre's aesthetic protocols address the underlying physiology - adipose tissue distribution, dermal collagen and copper-binding kinetics, regenerative signalling. Every compound is lot-tested, with biomarker tracking available. This is medicine, not a med-spa appointment.
The Vivre Approach
Lot-tested. Biomarker-anchored. Not protocol-on-demand.
Biological audit first
Every protocol starts with a comprehensive biological baseline - body composition, metabolic panel, inflammatory markers, hormone panel. We don't guess without data.
Lot-tested supply
Your results are mapped against optimal ranges in plain language. Some patients are better served by lifestyle interventions alone.
Continuous monitoring
Protocols include scheduled biomarker re-testing. We track your trajectory, not just outcomes. If something isn't responding, the markers show it.
Relevant ProtocolsLot-tested stacks
The protocols below address aesthetic and body-composition goals through distinct physiological mechanisms. Your audit determines which fits your case - frequently the answer is a combination, sequenced clinically.
The Peptides in These Protocols
Individual compounds
Patients often search by compound name (Tirzepatide, BPC-157, GHK-Cu) - not by protocol code. Here are the individual compounds that appear in Vivre's aesthetic protocols, grouped by what they do. Click any compound for its detailed clinical page, including evidence base, half-life, and mechanism.
GLP-1 metabolic medications
· appetite regulation, glucose handling, body weight
Note: individual compound pages exist for education and reference. Vivre's V-Series stacks package these compounds; individual compound pages exist for education and reference.
How It Works
01
Biological Audit
Comprehensive baseline - body composition, metabolic panel, inflammatory markers, hormone work. The audit takes approximately 60 minutes and provides the data foundation for everything that follows.
02
Read the Evidence
Every compound page sets out the evidence, the contraindications and the lot report. Honest scenarios include "not the right time for a peptide protocol" if biomarkers indicate other interventions first.
03
Lot-tested Supply
Protocol begins with the verified compound supply and the diagnostic scaffolding. Scheduled re-testing tracks biomarker trajectory. Adjustments are clinical, not promotional.
What Makes This Different
The medical-spa peptide market is large and varies enormously in quality. The distinguishing features of a clinically-credible programme:
Compound verification. Vivre's Double-Gate Protocol verifies every compound batch (HPLC purity + third-party mass spectrometry). Most medical-spa peptide programs do not.
Evidence first, not hype. Protocols are declined when biomarkers indicate they're not appropriate. Most direct-to-consumer programs sell to whoever asks.
Biomarker monitoring as standard. Vivre includes scheduled re-testing across protocol duration. Most programs monitor only at intake.
Evidence honesty. Vivre's compound pages document evidence quality openly - including when evidence is thin (e.g. Russian-origin neuropeptides, single-research-group bioregulators). Most retailer-grade content overstates evidence uniformly.
Evidence Base · Aesthetic Compounds
Primary sources · peer-reviewed
The compounds in Vivre's aesthetic protocols are supported by distinct evidence tiers - from Phase 3 RCTs to established human biochemistry to well-characterised preclinical mechanism. Vivre presents each at the level of evidence that actually exists.
Tier indicators (gold = human RCT, biochemistry, or genomic; amber = preclinical or investigational) reflect translational distance. Vivre presents human data prominently and flags preclinical evidence explicitly so you can weigh it honestly. Click any card for full study breakdown on the compound page.
Common Questions
Is this safe for me?
That is what a baseline panel helps answer. Some patients are better candidates for these protocols than others - the audit identifies contraindications. Honest answer: if biomarkers point to underlying issues that need addressing first, start there.
Will I regain the weight after the protocol?
For GLP-1-class compounds in particular, this is the central clinical question. The Vivre approach uses tissue-protective adjuncts (e.g. growth-hormone-axis support via Tesamorelin) alongside the metabolic intervention specifically to preserve lean mass during loss - which is the strongest predictor of sustained outcomes. Maintenance protocols and lifestyle support are part of the design.
What about menopause or perimenopause considerations?
Hormonal context affects how every protocol behaves. The baseline panel includes the hormone work. If hormone replacement may be appropriate, that is a conversation with your own doctor - Vivre does not provide HRT.
How is this different from Ozempic or Wegovy alone?
GLP-1 monotherapy produces meaningful weight loss but is associated with substantial lean-mass loss. Vivre's approach addresses this by pairing the metabolic intervention with tissue-protective and regenerative compounds, with biomarker monitoring throughout. Every compound is lot-tested and verified, with the report published.
How long does it take?
Initial audit appointment is approximately 60 minutes. Protocol begins after these two appointments and a brief biomarker-result review period.
Next Step
Start with the Biological Audit.
The audit provides the foundation. From there, you decide whether a stack fits.